Explore more publications!
Health Monitor Liechtenstein
Got News to Share?

Health Monitor Liechtenstein: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Monitor Liechtenstein.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on November 24, 2025

HealthLynked Engages NE Holdings, LLC to Lead Strategic Advisory Services for Nasdaq Listing
November 24, 2025

HealthLynked Engages NE Holdings, LLC to Lead Strategic Advisory Services for Nasdaq Listing

Indeterminate GlobeNewswire
Iterum Therapeutics Provides Business Update
November 24, 2025

Iterum Therapeutics Provides Business Update

Indeterminate GlobeNewswire
Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
November 24, 2025

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Indeterminate GlobeNewswire
Annovis Announces Two Presentations at the CTAD 2025 Conference
November 24, 2025

Annovis Announces Two Presentations at the CTAD 2025 Conference

Indeterminate GlobeNewswire
ProMIS Neurosciences Announces Reverse Stock Split
November 24, 2025

ProMIS Neurosciences Announces Reverse Stock Split

Indeterminate GlobeNewswire
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
November 24, 2025

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Indeterminate GlobeNewswire
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
November 24, 2025

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

Indeterminate GlobeNewswire
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
November 24, 2025

Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Indeterminate GlobeNewswire
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
November 24, 2025

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Indeterminate GlobeNewswire
LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME’s America’s Growth Leaders of 2026
November 24, 2025

LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME’s America’s Growth Leaders of 2026

Indeterminate GlobeNewswire
This Thanksgiving, Experts Want Parents to Know That Picky Eating Isn’t Always “Just Picky Eating”
November 24, 2025

This Thanksgiving, Experts Want Parents to Know That Picky Eating Isn’t Always “Just Picky Eating”

Indeterminate GlobeNewswire
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
November 24, 2025

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

Indeterminate GlobeNewswire
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board
November 24, 2025

Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Indeterminate GlobeNewswire
Vertero Initiates Phase 1 Study of VT-5006, A Selective Small Molecule Therapy for Parkinson’s Disease
November 24, 2025

Vertero Initiates Phase 1 Study of VT-5006, A Selective Small Molecule Therapy for Parkinson’s Disease

Indeterminate GlobeNewswire
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting
November 24, 2025

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

Indeterminate GlobeNewswire
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
November 24, 2025

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Indeterminate GlobeNewswire
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
November 24, 2025

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Indeterminate GlobeNewswire
Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million
November 24, 2025

Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million

Indeterminate GlobeNewswire
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
November 24, 2025

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Indeterminate GlobeNewswire
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
November 24, 2025

Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions